Anti-ELAP2/ KIAA1324L/ EIG121L monoclonal antibody

Anti-ELAP2/ KIAA1324L/ EIG121L antibody for FACS & in-vivo assay

Target products collectionGo to KIAA1324L/KIAA1324L products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0699-Ab-1/ GM-Tg-hg-MP0699-Ab-2Anti-Human KIAA1324L monoclonal antibodyHuman
GM-Tg-rg-MP0699-Ab-1/ GM-Tg-rg-MP0699-Ab-2Anti-Rat KIAA1324L monoclonal antibodyRat
GM-Tg-mg-MP0699-Ab-1/ GM-Tg-mg-MP0699-Ab-2Anti-Mouse KIAA1324L monoclonal antibodyMouse
GM-Tg-cynog-MP0699-Ab-1/ GM-Tg-cynog-MP0699-Ab-2Anti-Cynomolgus/ Rhesus macaque KIAA1324L monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0699-Ab-1/ GM-Tg-felg-MP0699-Ab-2Anti-Feline KIAA1324L monoclonal antibodyFeline
GM-Tg-cang-MP0699-Ab-1/ GM-Tg-cang-MP0699-Ab-2Anti-Canine KIAA1324L monoclonal antibodyCanine
GM-Tg-bovg-MP0699-Ab-1/ GM-Tg-bovg-MP0699-Ab-2Anti-Bovine KIAA1324L monoclonal antibodyBovine
GM-Tg-equg-MP0699-Ab-1/ GM-Tg-equg-MP0699-Ab-2Anti-Equine KIAA1324L monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0699-Ab-1/ GM-Tg-hg-MP0699-Ab-2; GM-Tg-rg-MP0699-Ab-1/ GM-Tg-rg-MP0699-Ab-2;
GM-Tg-mg-MP0699-Ab-1/ GM-Tg-mg-MP0699-Ab-2; GM-Tg-cynog-MP0699-Ab-1/ GM-Tg-cynog-MP0699-Ab-2;
GM-Tg-felg-MP0699-Ab-1/ GM-Tg-felg-MP0699-Ab-2; GM-Tg-cang-MP0699-Ab-1/ GM-Tg-cang-MP0699-Ab-2;
GM-Tg-bovg-MP0699-Ab-1/ GM-Tg-bovg-MP0699-Ab-2; GM-Tg-equg-MP0699-Ab-1/ GM-Tg-equg-MP0699-Ab-2
Products NameAnti-KIAA1324L monoclonal antibody
Formatmab
Target NameKIAA1324L
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-KIAA1324L benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species ELAP2/ KIAA1324L/ EIG121L VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0699
    Target NameKIAA1324L
    Gene ID222223,231014,502727,707191,475216,101096049,518313,100058929
    Gene Symbol and Synonyms9330182L06Rik,EIG121L,ELAPOR2,KIAA1324L,RGD1563349
    Uniprot AccessionA8MWY0,A7E2Z9
    Uniprot Entry NameELAP2_HUMAN,ELAP2_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000164659
    Target ClassificationN/A

    The target: KIAA1324L, gene name: KIAA1324L, also named as EIG121L. Predicted to enable BMP receptor binding activity. Predicted to be involved in negative regulation of nervous system development; positive regulation of BMP signaling pathway; and positive regulation of epidermis development. Predicted to be located in plasma membrane. Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.